Role of Anti-PD-L1 Therapy in Lymphatic Malformations Rat Models

doi:10.13701/j.cnki.kqyxyj.2020.04.006

Abstract

Abstract: Objective: To observe the effect of Anti-PD-L1 therapy in established LMs rat models. Methods: LMs rat models were established by injection of Freund's incomplete adjuvant (FIA) in subcutaneous to the neck in twenty female Wistar rats [(250 ± 30) g]. Rats with lesions were randomly divided into four groups with different treatment as follows: PBS only, PBS and Anti-PD-L1, PBS and LPS or PBS combination with LPS and Anti-PD-L1. The sizes of LMs lesions and body weight of rats were measured for every week. After eight weeks, all rats were euthanized and the cystic lesions and vital visceral organs were harvested for further investigation. Expression level of PD-L1 in normal skins and human LMs was detected by immunohistochemistry. Results: PD-L1 was strongly elevated in the LM lesions of rats and further increased in the presence of LPS. Anti-PD-L1 therapy showed satisfactory therapeutic effect on both non-inflammatory and inflammatory LMs by decreasing the proliferation and tubular formation of lymphatic endothelial cells. In addition, compared with normal skins, PD-L1 was also upregulated in human LM lesions. Conclusion: PD-L1 might contribute to the pathological process of lymphatic malformations. Targeting the PD-L1 might be a promising therapeutic strategy for LMs.

Key words: programmed death-ligand 1, lymphatic malformations, rat models

JIANG Hao, ZHONG Wenqun, ZOU Yanping, LI Xuecong, CAI Yu. Role of Anti-PD-L1 Therapy in Lymphatic Malformations Rat Models[J]. Journal of Oral Science Research, 2020, 36(4): 328-332.

References

[1] Perkins JA, Manning SC, Tempero RM, et al. Lymphatic malformations: current cellular and clinical investigations [J]. Otolaryngol Head Neck Surg, 2010, 142(6): 789-794.
[2] Ren JG, Xia HF, Yang JG, et al. Down-regulation of polycystin in lymphatic malformations: possible role in the proliferation of lymphatic endothelial cells [J]. Hum Pathol, 2017, 65: 231-238.
[3] Tokumoto M, Tanaka H, Tauchi Y, et al. Immunoregulatory function of lymphatic endothelial cells in tumor-draining lymph nodes of human gastric cancer [J]. Anticancer Res, 2017, 37(6): 2875-2883.
[4] Bordry N, Broggi MAS, de Jonge K, et al. Lymphatic vessel density is associated with CD8(+) T cell infiltration and immunosuppressive factors in human melanoma [J]. Oncoimmunology, 2018, 7(8): e1462878.
[5] Yang JG, Sun YF, He KF, et al. Lymphotoxins promote the progression of human lymphatic malformation by enhancing lymphatic endothelial cell proliferation [J]. Am J Pathol, 2017, 187(11): 2602-2615.
[6] Banerji S, Ni J, Wang SX, et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan[J]. J Cell Biol, 1999, 144(4): 789-801.
[7] 孙志军,武磊.口腔鳞状细胞癌免疫检查点的研究进展[J].口腔医学研究, 2019, 35(12): 1107-1110.
[8] Defnet AM, Bagrodia N, Hernandez SL, et al. Pediatric lymphatic malformations: evolving understanding and therapeutic options [J]. Pediatr Surg Int, 2016, 32(5): 425-433.
[9] Lokmic Z, Mitchell GM, Koh Wee Chong N, et al. Isolation of human lymphatic malformation endothelial cells, their in vitro characterization and in vivo survival in a mouse xenograft model [J]. Angiogenesis, 2014, 17(1): 1-15.
[10] Zhang W, He KF, Yang JG, et al. Infiltration of M2-polarized macrophages in infected lymphatic malformations: possible role in disease progression [J]. Br J Dermatol, 2016, 175(1): 102-112.
[11] Glaser K, Dickie P, Neilson D, et al. Linkage of metabolic defects to activated PIK3CA alleles in endothelial cells derived from lymphatic malformation [J]. Lymphat Res Biol, 2018, 16(1): 43-55.
[12] Lane RS, Femel J, Breazeale AP, et al. IFNgamma-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin [J]. J Exp Med, 2018, 215(12): 3057-3074.
[13] Lucas ED, Finlon JM, Burchill MA, et al. Type 1 IFN and PD-L1 coordinate lymphatic endothelial cell expansion and contraction during an inflammatory immune response [J]. J Immunol, 2018, 201 (6): 1735-1747.